GlassScriptPhysician profile
Andrew I Rackoff
NPI 1740489145
$7,255.15
in general payments reported to CMS, 2019-2025
30 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $533 · 2021: $743 · 2022: $1,412 · 2023: $1,412 · 2024: $1,114 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738 · Education: $46.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,737.68 |
| Education | $46.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,162.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $933.20 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $755.13 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $667.02 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $453.99 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $316.10 | 2019-2024 | Linzess |
| Pfizer INC. | $186.49 | 2019-2025 | |
| Qol Medical, LLC | $185.60 | 2023-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $153.53 | 2022-2023 | Rebyota, Cimzia |
| Phathom Pharmaceuticals, INC. | $149.56 | 2024-2025 | Voquezna |
| Celgene Corporation | $123.56 | 2021-2023 | Zeposia |
| Genzyme Corporation | $106.58 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $101.13 | 2025 | Iqirvo |
| Celltrion USA INC. | $91.80 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $87.16 | 2025 | Rezdiffra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $84.80 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $83.87 | 2019-2025 | Ocaliva |
| Romark Laboratories, Lc | $76.11 | 2019-2020 | |
| Lilly USA, LLC | $71.05 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $64.60 | 2025 | Wegovy |
| Endogastric Solutions, INC | $62.57 | 2019 | |
| Organon LLC | $57.89 | 2023-2024 | Hadlima |
| Ardelyx, INC. | $57.72 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $54.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.71 | 2023-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $45.18 | 2020-2023 | Dificid |
| Braintree Laboratories, INC. | $31.70 | 2019-2023 | Sutab |
| Fresenius Kabi USA, LLC | $16.93 | 2023 | Idacio |
| Shionogi INC | $15.15 | 2019 | |
| Ucb, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rackoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.